Farah Champsi joined InterWest Partners as a managing director in May 2015. Since 2000, she has been a managing director at Alta Partners and played a key role in raising and managing over $1 billion in life sciences venture funds. She currently serves on the boards of Allakos and Kite Pharma. Farah is also responsible for Alta's investments in Cytokinetics, Intarcia, and Trevena. Previously, she led Alta's investments in Agensys (acquired by Astellas), Esperion (acquired by Pfizer), Excaliard (acquired by Pfizer), Orphan Medical (acquired by Jazz), Chimerix (IPO) and Portola (IPO).
Prior to joining Alta in 2000, Farah was an investment banker for 13 years at Robertson Stephens & Company, where she focused on biotechnology and other life sciences companies. She was elected head of the global life sciences investment banking group in 1995. During that time, she was responsible for building one of the most successful life sciences investment banking franchises on Wall Street.
In 2016 Farah was named as one of the top 15 women in biotech by FiercePharma, a leading publication in the biotech industry.
Farah received an M.B.A. from Stanford University and a B.A. in Economics from Smith College. She serves on the board of UCSF Benioff Children’s Hospitals.